Our client is developing best-in-class antibodies to neutralise coronaviruses. Our client wanted to...
Read moreOur client required focused payer value messages for their PUMA product as payers were not recognisi...
Read moreOur client required focused payer value messages for their PUMA product as payers were not recognizi...
Read moreOur client wanted to broaden access and funding for their reproduction biosimilar in the UK. However...
Read moreOur client is developing an innovative medical device for use in Type 2 diabetes (T2D). The client w...
Read moreOur client has developed an innovative digital health platform to prevent falls. Due to the platform...
Read moreOur client felt that their current value proposition was insufficient in communicating the benefits ...
Read moreOur client wanted to undertake joint payer scientific advice between the EMA and 5 national HTA bodi...
Read moreConduct a rapid pricing and market access (P&MA) assessment across the US and EU5 in order to determ...
Read moreOur client had concerns as to whether the clinical end-points in their phase III trial were relevant...
Read more